Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup analysis from the CheckMate 025 study-Reference-Cited by-同舟云学术

Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup analysis from the CheckMate 025 study

Published:2017-04-13 Issue:7 Volume:47 Page:639-646
ISSN:0368-2811
Container-title:Japanese Journal of Clinical Oncology
language:en
Short-container-title:

Author:

Tomita Yoshihiko¹²,Fukasawa Satoshi³,Shinohara Nobuo⁴,Kitamura Hiroshi⁵⁶,Oya Mototsugu⁷,Eto Masatoshi⁸⁹,Tanabe Kazunari¹⁰,Kimura Go¹¹,Yonese Junji¹²,Yao Masahiro¹³,Motzer Robert J.¹⁴,Uemura Hirotsugu¹⁵,McHenry M. Brent¹⁶,Berghorn Elmer¹⁷,Ozono Seiichiro¹⁸

Affiliation:

1. Department of Urology, Yamagata University Hospital, Yamagata

2. Current affiliation: Department of Urology, Molecular Oncology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan

3. Prostate Center and Division of Urology, Chiba Cancer Center, Chiba

4. Department of Urology, Hokkaido University, Sapporo

5. Department of Urology, Sapporo Medical University Hospital, Sapporo

6. Current affiliation: Department of Urology, University of Toyama, Toyama, Japan

7. Department of Urology, Keio University Hospital, Tokyo

8. Department of Urology, Kumamoto University, Kumamoto

9. Current affiliation: Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

10. Department of Urology, Tokyo Women's Medical University Hospital, Tokyo

11. Department of Urology, Nippon Medical School Hospital, Tokyo

12. Department of Urology, Cancer Institute Hospital, Tokyo

13. Department of Urology, Yokohama City University Hospital, Yokohama, Japan

14. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA

15. Department of Urology, Kindai University Faculty of Medicine, Osaka, Japan

16. Global Biometric Sciences, Bristol-Myers Squibb, Princeton, NJ, USA

17. Global Clinical Research, Bristol-Myers Squibb, Princeton, NJ, USA

18. Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan

Funder

Bristol-Myers Squibb

Ono Pharmaceutical Company Limited

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology,General Medicine

Link

http://academic.oup.com/jjco/article-pdf/47/7/639/26647203/hyx049.pdf

Reference22 articles.

1. Pharmacotherapies for renal cell carcinoma in Japan;Yoshimura;Int J Urol,2016

2. Nivolumab versus everolimus in advanced renal-cell carcinoma;Motzer;N Engl J Med,2015

3. Kidney Cancer Working Group report;Naito;Jpn J Clin Oncol,2010

4. Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart review;Oh;Int J Oncol,2014

5. Risk factors for sorafenib-induced high-grade skin rash in Japanese patients with advanced renal cell carcinoma;Tsuchiya;Anticancer Drugs,2013

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. From glioma gloom to immune bloom: unveiling novel immunotherapeutic paradigms-a review;Journal of Experimental & Clinical Cancer Research;2024-02-12

2. Clinical factors for tumor response, progression, and survival in nivolumab for advanced renal cell carcinoma in the SNiP‐RCC study;International Journal of Urology;2023-08

3. Real‐world effectiveness of nivolumab and subsequent therapy in Japanese patients with metastatic renal cell carcinoma (POST‐NIVO study): 36‐month follow‐up results of a clinical chart review;International Journal of Urology;2023-05-29

4. Outcomes of responders to PD-1/PD-L1 inhibitors who discontinue therapy after sustained disease control;Journal of Cancer Research and Clinical Oncology;2023-04-28

5. Combined Use of Immune Checkpoint Inhibitors and Phytochemicals as a Novel Therapeutic Strategy against Cancer;Journal of Cancer;2023